Flufenamic acid cas no:530-78-9
Synonyms: N-(alpha,alpha,alpha-Trifluoro-m-tolyl)anthranilic acid; Flufenamic acid (base and/or unspecified salts); N-(3-Trifluoromethylphenyl)anthranilic acid
NameFlufenamic acid
CAS530-78-9
SynonymsN-(alpha,alpha,alpha-Trifluoro-m-tolyl)anthranilic acid; Flufenamic acid (base and/or unspecified salts); N-(3-Trifluoromethylphenyl)anthranilic acid
EINECS(EC#)208-494-1
Molecular FormulaC14H10F3NO2
Molecular Weight281.23
AppearanceWhite
to light yellow crystalline powder
refractive index1.585
storage tempStore in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Globally Harmonized System of Classification adn Labelling of Chemicals(GHS)
Hazardclass6.1(b)
Hazard Xn:Harmful;
Risk R22;R36/38
Safety
Poison by ingestion, intravenous, and intraperitoneal routes. Experimental reproductive effects. Human systemic effects: hypermotility, diarrhea. Human mutation data reported. When heated to decomposition it emits very toxic fumes of F− and NOx. Used as an anti-inflammatory agent. See also FLUORIDES.
Hazard Codes:
Xi: Irritant .gif)
Risk Statements about N-(α,α,α-TRIFLUORO-m-TOLYL)ANTHRANILIC ACID (530-78-9):
R21/22 Harmful in contact with skin and if swallowed.
R36/37/38 Irritating to eyes, respiratory system and skin.
Safety Statements about N-(α,α,α-TRIFLUORO-m-TOLYL)ANTHRANILIC ACID (530-78-9):
S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.
Attentions:
1. Storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
2. Handling: Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation.
| 1. |
|
dni-hmn-unr 504 mg/kg/8W
|
|
STBIBN Studia Biophysica. 50 (1975),172. |
| 2. |
|
orl-wmn TDLo:2160 mg/kg/26W-I:GIT
|
|
PGMJAO Postgraduate Medical Journal. 62 (1986),773. |
| 3. |
|
orl-rat LD50:249 mg/kg
|
|
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. 221 (1976),132. |
| 4. |
|
ipr-rat LD50:185 mg/kg
|
|
OYYAA2 Oyo Yakuri. Pharmacometrics. 16 (1978),1011. |
| 5. |
|
ivn-rat LD50:98 mg/kg
|
|
CMROCX Current Medical Research and Opinion. 4 (1976),17. |
| 6. |
|
orl-mus LD50:490 mg/kg
|
|
OYYAA2 Oyo Yakuri. Pharmacometrics. 16 (1978),1011. |
| 7. |
|
ipr-mus LD50:150 mg/kg
|
|
NTIS** National Technical Information Service. (Springfield, VA 22161) (Formerly U.S. Clearinghouse for Scientific and Technical Information) AD691-490 . |
| 8. |
|
ivn-mus LD50:158 mg/kg
|
|
YKKZAJ Yakugaku Zasshi. Journal of Pharmacy. 89 (1969),1392. |
